The Indianapolis-based drugmaker said the deal to buy Protomer Technologies could be worth up to $1 billion if the technology meets certain milestones. Lilly did not say how much it was paying up front in cash.
Quantigen Biosciences plans Fishers expansion, 30 new jobs
Fishers-based Quantigen Biosciences is spending $2.5 million to redevelop 40,000 square feet of office space along Interstate 69 as its new specialty contract research laboratory.Read More
Genetically modified salmon from Indiana head to U.S. dinner plates
Several tons of salmon, engineered by biotech company AquaBounty Technologies Inc. and raised in Indiana, are heading to restaurants and dining services for the first time.Read More
Lilly acquiring gene therapy startup for up to $1 billion
Eli Lilly and Co. on Tuesday announced that it is buying New York-based Prevail Therapeutics Inc., an emerging player in the sizzling-hot area of gene therapies, which targets Parkinson’s disease and other brain-related maladies.Read More
Elanco to cut 900 jobs in 40 countries following Bayer acquisition
The layoff is the first step in what is expected to be a major restructuring following Greenfield-based Elanco’s $6.9 billion acquisition of German conglomerate Bayer AG’s animal-health division.Read More
The radiopharmaceutical developer and manufacturer is the latest in a string of life sciences firms that have announced plans to grow operations in Fishers.
The new gadget from VoCare Inc. is about the size of a smart phone and measures a person’s temperature, heart rate, blood pressure, blood glucose levels, blood oxygen saturation and heart rhythms.
Much of the money is earmarked to acquire a 75-acre property for a life sciences business park that will be anchored by Stevanato Group’s planned $145 million pharmaceutical manufacturing facility.
Stevanato Group, a producer of syringes, vials and glass containers, announced Wednesday it will spend $145 million to build and equip a 370,000-square-foot facility in Fishers.
The company, with headquarters and a massive factory on the northwest side, has hired about 100 people in the past year, bringing its workforce to about 550. And it’s looking to hire another 100 people this year.
Matthew Sause took the helm of the 4,500-person Roche Diagnostics’ North American operations in Indianapolis in November 2019—just four months before the World Health Organization declared a pandemic and much of the planet went into lockdown.
This is a partial transcript of IBJ’s annual Life Sciences Power Panel, which took place virtually on April 30 with four of Indy’s biosciences leaders: 16 Tech CEO Bob Coy, GenePace Laboratories founder Sanjay Malkani, Elanco Animal Health CEO Jeff Simmons and Indiana University School of Medicine geneticist Tatiana Foroud.
Speakers at the IBJ Life Sciences Power Panel on Friday said their organizations have largely weathered the lockdown—raising records funds, taking on huge expansions, hiring new employees and reporting higher productivity.
The expansion will consist of 32 new one-bedroom apartments and five two-bedroom residences, bringing to 67 the number of assisted-living apartments at the complex.
The legislation, Senate Bill 202, would allow designated family members to visit residents under end-of-life and other serious circumstances.
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Genezen Laboratories Inc. says new funding from a Massachusetts-based private equity firm will allow it to expand its plans for a new production facility in Fishers Crosspoint Business Park.
The state’s new dashboard on COVID-19 vaccines provides interesting breakdowns on who is getting vaccinated, by county, by gender, by race, by age and a host of other statistics sure to please any proud data geek.
The 39 companies that won venture funding represent a wide range of therapeutics, devices and health information technology.
Last week, state health officials said they expected to initially receive 55,575 doses of Pfizer’s COVID-19 vaccine, and had already begun vaccinating front-line health care workers. But just five days later, state officials and hospitals are keeping mum about how many doses they actually received, except to say it was fewer than expected.
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
CEO Jeff Simmons said the company’s high-profile downtown Indianapolis headquarters will signal a cultural transformation at the company, which for most of its six decades of existence operated as a little-noticed subsidiary of Eli Lilly and Co.
In every significant statistical category, November has been a record-setter for the COVID-19 pandemic in Indiana, with cases, deaths and hospitalizations far exceeding even the early months of the coronavirus outbreak.
Despite the change in fortunes, Ascension signaled that it is not yet out of the woods, noting that “consumer confidence and healthcare hesitation as a result of COVID-19 continue to affect Ascension markets, to varying degrees.”